{
  "citations" : [ {
    "@id" : "https://pharmgkb.org/literature/15128762",
    "@context" : "https://api.pharmgkb.org/jsonld/literature.jsonld",
    "id" : 15128762,
    "title" : "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms.",
    "_sameAs" : "https://www.ncbi.nlm.nih.gov/pubmed/35152405",
    "authors" : [ "Cooper-DeHoff Rhonda M", "Niemi Mikko", "Ramsey Laura B", "Luzum Jasmine A", "Tarkiainen E Katriina", "Straka Robert J", "Gong Li", "Tuteja Sony", "Wilke Russell A", "Wadelius Mia", "Larson Eric A", "Roden Dan M", "Klein Teri E", "Yee Sook Wah", "Krauss Ronald M", "Turner Richard M", "Palaniappan Latha", "Gaedigk Andrea", "Giacomini Kathleen M", "Caudle Kelly E", "Voora Deepak" ],
    "crossReferences" : [ {
      "@id" : "https://pharmgkb.org/crossReference/pubMed/35152405",
      "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
      "id" : 1451681580,
      "resource" : "PubMed",
      "resourceId" : "35152405",
      "_url" : "https://www.ncbi.nlm.nih.gov/pubmed/35152405",
      "version" : 0
    }, {
      "@id" : "https://pharmgkb.org/crossReference/doi/10.1002/cpt.2557",
      "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
      "id" : 1451681581,
      "resource" : "DOI",
      "resourceId" : "10.1002/cpt.2557",
      "_url" : "http://dx.doi.org/10.1002%2Fcpt.2557",
      "version" : 0
    } ],
    "hasKeyword" : true,
    "journal" : "Clinical pharmacology and therapeutics",
    "meshDiseases" : [ ],
    "meshTerms" : [ ],
    "month" : 2,
    "nonHuman" : false,
    "objCls" : "Literature",
    "pediatric" : false,
    "pgkbPublication" : true,
    "pubDate" : "2022-02-01T00:00:00-08:00",
    "summary" : "Statins reduce cholesterol, prevent cardiovascular disease, and are among the most commonly prescribed medications in the world. Statin-associated musculoskeletal symptoms (SAMS) impact statin adherence and ultimately can impede the long-term effectiveness of statin therapy. There are several identified pharmacogenetic variants that impact statin disposition and adverse events during statin therapy. SLCO1B1 encodes a transporter (SLCO1B1; alternative names include OATP1B1 or OATP-C) that facilitates the hepatic uptake of all statins. ABCG2 encodes an efflux transporter (BCRP) that modulates the absorption and disposition of rosuvastatin. CYP2C9 encodes a Phase-I drug metabolizing enzyme responsible for the oxidation of some statins. Genetic variation in each of these genes alters systemic exposure to statins (i.e., simvastatin, rosuvastatin, pravastatin, pitavastatin, atorvastatin, fluvastatin, lovastatin), which can increase the risk for SAMS. We summarize the literature supporting these associations and provide therapeutic recommendations for statins based on SLCO1B1, ABCG2, and CYP2C9 genotype with the goal of improving the overall safety, adherence and effectiveness of statin therapy. This document replaces the 2012 and 2014 Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for SLCO1B1 and simvastatin-induced myopathy.",
    "version" : 1,
    "year" : 2022
  } ],
  "guideline" : {
    "@id" : "https://pharmgkb.org/guidelineAnnotation/PA166262661",
    "@context" : "https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld",
    "objCls" : "Guideline Annotation",
    "id" : "PA166262661",
    "name" : "Annotation of CPIC Guideline for atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, simvastatin and ABCG2",
    "cancerGenome" : false,
    "crossReferences" : [ ],
    "descriptiveVideoId" : "krWRm5iMLaY",
    "guidelineGenes" : [ ],
    "history" : [ {
      "id" : 1451687101,
      "date" : "2022-02-17T00:00:00-08:00",
      "description" : "CPIC statins 2022 update",
      "type" : "Note",
      "version" : 1
    }, {
      "id" : 1451694002,
      "date" : "2022-02-23T14:00:05.487-08:00",
      "description" : "Added video",
      "type" : "Update",
      "version" : 0
    } ],
    "literature" : [ {"@id":"https://pharmgkb.org/literature/15128762","@context":"https://api.pharmgkb.org/jsonld/literature.jsonld","id":15128762,"title":"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms.","_sameAs":"https://www.ncbi.nlm.nih.gov/pubmed/35152405","crossReferences":[{"@id":"https://pharmgkb.org/crossReference/pubMed/35152405","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1451681580,"resource":"PubMed","resourceId":"35152405","_url":"https://www.ncbi.nlm.nih.gov/pubmed/35152405"},{"@id":"https://pharmgkb.org/crossReference/doi/10.1002/cpt.2557","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1451681581,"resource":"DOI","resourceId":"10.1002/cpt.2557","_url":"http://dx.doi.org/10.1002%2Fcpt.2557"}],"objCls":"Literature"} ],
    "pediatric" : false,
    "recommendation" : false,
    "relatedAlleles" : [ ],
    "relatedChemicals" : [ {
      "@id" : "https://pharmgkb.org/chemical/PA448500",
      "@context" : "https://api.pharmgkb.org/jsonld/chemical.jsonld",
      "objCls" : "Chemical",
      "id" : "PA448500",
      "name" : "atorvastatin",
      "version" : 21
    }, {
      "@id" : "https://pharmgkb.org/chemical/PA449688",
      "@context" : "https://api.pharmgkb.org/jsonld/chemical.jsonld",
      "objCls" : "Chemical",
      "id" : "PA449688",
      "name" : "fluvastatin",
      "version" : 21
    }, {
      "@id" : "https://pharmgkb.org/chemical/PA450272",
      "@context" : "https://api.pharmgkb.org/jsonld/chemical.jsonld",
      "objCls" : "Chemical",
      "id" : "PA450272",
      "name" : "lovastatin",
      "version" : 20
    }, {
      "@id" : "https://pharmgkb.org/chemical/PA142650384",
      "@context" : "https://api.pharmgkb.org/jsonld/chemical.jsonld",
      "objCls" : "Chemical",
      "id" : "PA142650384",
      "name" : "pitavastatin",
      "version" : 3
    }, {
      "@id" : "https://pharmgkb.org/chemical/PA451089",
      "@context" : "https://api.pharmgkb.org/jsonld/chemical.jsonld",
      "objCls" : "Chemical",
      "id" : "PA451089",
      "name" : "pravastatin",
      "version" : 20
    }, {
      "@id" : "https://pharmgkb.org/chemical/PA451363",
      "@context" : "https://api.pharmgkb.org/jsonld/chemical.jsonld",
      "objCls" : "Chemical",
      "id" : "PA451363",
      "name" : "simvastatin",
      "version" : 23
    } ],
    "relatedGenes" : [ {
      "@id" : "https://pharmgkb.org/gene/PA390",
      "@context" : "https://api.pharmgkb.org/jsonld/gene.jsonld",
      "objCls" : "Gene",
      "id" : "PA390",
      "symbol" : "ABCG2",
      "name" : "ATP binding cassette subfamily G member 2 (Junior blood group)",
      "version" : 3595
    } ],
    "source" : "CPIC",
    "summaryMarkdown" : {
      "id" : 1451673160,
      "html" : "<p>There are currently no recommendations for atorvastatin, lovastatin, fluvastatin, pravastatin, pitavastatin and simvastatin dosing based on ABCG2 genotypes.</p>\n",
      "version" : 0
    },
    "terms" : [ ],
    "textMarkdown" : {
      "id" : 1451673161,
      "html" : "<p>This annotation is based on the <a rel=\"noopener noreferrer\" href=\"https://cpicpgx.org/guidelines/cpic-guideline-for-statins/\" target=\"_blank\">CPIC&reg; guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms</a>.</p>\n<h3 id=\"feburary-2022-update\">Feburary 2022 Update</h3>\n<ul>\n<li>\n<p>The <a rel=\"noopener noreferrer\" href=\"https://ascpt.onlinelibrary.wiley.com/doi/epdf/10.1002/cpt.2557\" target=\"_blank\">CPIC guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms</a>, has been published in Clinical Pharmacology and Therapeutics. CPIC authors summarize literature supporting how SLCO1B1, ABCG2, and CYP2C9 genotype test results should be applied to optimize new or existing statin therapy to reduce the risk of statin-associated musculoskeletal symptoms (SAMS). The current document replaces the original 2012 guideline and the 2014 update for SLCO1B1 and simvastatin. New to this guideline are the addition of recommendations for CYP2C9 and ABCG2 and addition of recommendations for all statins.</p>\n</li>\n<li>\n<p>This guideline is applicable to:</p>\n<ul>\n<li>adult patients</li>\n<li>pediatric patients</li>\n</ul>\n</li>\n<li>\n<p>Excerpt from the 2022 statin dosing guideline:</p>\n<ul>\n<li>&quot;ABCG2. Recommendations for ABCG2 are specific to rosuvastatin (Table 3). For individuals who have ABCG2 poor function, a rosuvastatin starting dose of â‰¤20mg is recommended; however, if a dose greater than 20mg is needed for desired efficacy, an alternative statin or combination therapy (e.g., statin + ezetimibe) is recommended. Although the risk of myopathy is unknown, rosuvastatin exposure (AUC) was 144% greater in those with the c.421AA genotype than the c.421CC genotype (wild-type); thus, the recommendation is based primarily on pharmacokinetic data. Likely because of the higher hepatic exposure, the ABCG2 c.421A variant has also been associated with improved cholesterol lowering response to rosuvastatin in large genomewide association studies. Selection and dosing of rosuvastatin should also consider Asian ancestry (Table 3, see the Supplemental Material for more discussion). Atorvastatin pharmacokinetics are also affected by ABCG2 genetic variation; however, at this time, there is insufficient evidence to provide a recommendation (no recommendation, CPIC level C). As noted previously, there is also limited evidence for providing recommendations for other statins based on genetic variation in ABCG2.&quot;</li>\n</ul>\n</li>\n<li>\n<p>Download and read:</p>\n<ul>\n<li><a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/guideline/publication/statins/2022/publication.pdf\" target=\"_blank\">The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms</a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/guideline/publication/statins/2022/supplement.pdf\" target=\"_blank\">2022 supplement</a></li>\n</ul>\n</li>\n</ul>\n",
      "version" : 2
    },
    "userId" : "lgong",
    "version" : 5
  }
}